Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
Clinical trial NCT05765084 · RECRUITING
Trial details
- NCT number
- NCT05765084
- Sponsor
- University Hospital, Antwerp
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-24
- Primary completion
- 2027-10-01
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.